

Hamilton Regional Laboratory Medicine Program - HRLMP (effective at Hamilton Health Sciences, St. Joseph's Healthcare and Associated Health Care Facilities)		
Initial Issue Date: Revision Date:	Administration Guidelines	Section: Laboratory Medicine Sub-Section: Transfusion Medicine
Title: HEPATITIS B IMMUNE GLOBULIN		Document Number:
Approved By: Director, Laboratory Medicine Chair, Regional Transfusion Medicine Committee Head, Transfusion Medicine, HRLMP Manager, Transfusion Medicine, HRLMP Technical Specialist, Transfusion Medicine, HRLMP Chief of Nursing Practice, Hamilton Health Sciences Chief of Nursing Practice, St. Joseph's Healthcare		Page 1 of 3

Purpose: To Establish the Indications and Administration of Hepatitis B Immune Globulin

Scope: Applies to all patient care areas across HHS and St. Joseph's Healthcare

Definitions: HBIG is treated with solvent/detergent and is a sterile solution of hepatitis B hyperimmune prepared by cold ethanol fractionation from the plasma of donors with high titres of antibody to hepatitis B surface antigen.

Other Names: Bay Hep B, HBIG (HUMAN)	Date Approved:	Pages: 1 of 3
---	-----------------------	----------------------

<p>INDICATIONS:</p> <ul style="list-style-type: none"> - Acute exposure to blood containing HBsAg - Perinatal exposure of infants born to HBsAg - positive mothers - Sexual exposure to an HBsAg - positive person - Household exposure to persons with active HBV infection
<p>DOSAGE:</p> <ul style="list-style-type: none"> - 0.5 mL HBIG administered intramuscularly to the newborn infant after physiologic stabilization of the infant and within 12 hrs of birth. (Hepatitis B Immune Globulin efficacy decreased markedly if treatment is delayed beyond 48hrs.) - Over 12 months of age, dosage varies for each patient, but is dependent on patient's weight (dose: 0.06 mL/Kg) - Acute exposure to blood containing HBsAg and Prophylaxis to infants born of HBsAg, positive mother's HBIG should be administered within 24 to 48 hours of exposure - Sexual exposure to Hepatitis BsAg-positive person HBIG should be given as soon as possible and up to 14 days of sexual contact
<p>SUPPLIED:</p> <ul style="list-style-type: none"> - Stored between 2°C and 8°C (36°F and 46°F) - Do not freeze - Do not use after expiry date - Single use vials: <ul style="list-style-type: none"> - 0.5 mL single dose syringe with attached needle - 1 mL vial - 5 mL vial

RECONSTITUTION AND STABILITY:

- Refer to Package Insert
- Once entered, discard any unused contents
- Do not use past expiry date

ADMINISTRATION:

METHOD	WHO/WHERE	DILUTION	HOW TO ADMINISTER	INFUSION PUMP	PRECAUTIONS AND MONITORING
IV PUSH	N/A	N/A	N/A	N/A	N/A
MINIBAG/ BURETROL	N/A	N/A	N/A	N/A	N/A
PRIMARY IV BAG	N/A	N/A	N/A	N/A	N/A
IM or SC	RN	No	- administer intramuscularly 0.06 mL/Kg body weight	No	- Observe and monitor for adverse reactions

COMPATIBILITIES/INCOMPATIBILITIES:

- It is not known whether Hepatitis B Immune Globulin may interfere with other live virus vaccines(unknown); therefore, use of such vaccines should be deferred until approximately 3 months after Hepatitis B Immune Globulin administration
- Hepatitis B vaccine may be administered at the same time but, at a different injection site, without interfering with the immune response

ADVERSE EFFECTS:

ALL ADVERSE REACTIONS MUST BE REPORTED TO TRANSFUSION MEDICINE

- Local pain and tenderness at the injection site
- Urticaria and angioedema may occur
- Anaphylactic reactions, although rare, have been reported following the injection of human immune globulin preparations
- Epinephrine must be available to treat severe symptoms

MANAGEMENT OF ADVERSE EFFECTS:

- Notify Physician
- Notify Transfusion Medicine
- Although no data is available, clinical experience with other immunoglobulin preparations suggests that the only manifestations would be pain and tenderness at the injection site

NOTES:

- Manufactured by Bayer Corporation
- Distributed by Canadian Blood Services

Documentation:

Issue transfuse sheets or requisitions with lot number must be included in patient's chart. Written consent for transfusion is required prior to administration.

9.0 References

Package Insert - Hepatitis B Immune Globulin (Human), Bay Hep ®, Bayer Corporation November 1999.

10.0 Developed By In Consultation With

Transfusion Medicine Operations Group
Pediatric Clinical Nurse Educators

<i>REVIEW DATES:</i>

<i>REVISION DATES:</i>
